Zobrazeno 1 - 10
of 559
pro vyhledávání: '"P Thuß-Patience"'
Autor:
Anne Dörr, Insa Vogel, Friedrich Wittenbecher, Jörg Westermann, Peter Thuss-Patience, Johann Ahn, Uwe Pelzer, Juliane Hardt, Lars Bullinger, Anne Flörcken
Publikováno v:
Palliative Care and Social Practice, Vol 18 (2024)
Background: Due to modern therapies, survival in metastatic renal cell carcinoma (mRCC) has been significantly prolonged. Nevertheless, patients suffering from advanced disease often present with severe symptoms. Early integration of palliative care
Externí odkaz:
https://doaj.org/article/83359c14034745fbb1c4ff7cb53a3da0
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alessandro Lorusso, Dmitry Bichev, Anica Högner, Prisca Bartels, Alexej Ballhausen, Christoph Treese, Matthias Biebl, Peter Thuss-Patience
Publikováno v:
Current Oncology, Vol 29, Iss 4, Pp 2706-2719 (2022)
The prognostic meaning of weight loss (WL) during standard treatment for operable oesophagogastric cancer is still unclear. The aim of this study is to analyse the prognostic effect of WL during perioperative chemotherapy (PC) for gastric cancer (GC)
Externí odkaz:
https://doaj.org/article/df8381edd5ec429aa489f58c10d3c84e
Autor:
Peter Thuss-Patience, Alexander Stein
Publikováno v:
Current Oncology, Vol 29, Iss 4, Pp 2461-2471 (2022)
Treatment of esophageal carcinoma has changed dramatically following several landmark trials, which have proven the benefit of immunotherapy. The selective PD-1 (programmed cell death ligand-1)-inhibitor nivolumab has been shown to improve DFS in the
Externí odkaz:
https://doaj.org/article/487a1180363f4ea5a99b9a608dd5850b
Autor:
Alexej Ballhausen, Prisca Bartels, Ines Iacovella, Anica Hoegner, Alessandro Lorusso, Dmitry Bichev, Severin Daum, Peter Thuss-Patience
Publikováno v:
Current Oncology, Vol 29, Iss 3, Pp 1983-1996 (2022)
Perioperative chemotherapy is the standard of care for patients undergoing curative resection for gastroesophageal adenocarcinoma. However, less than 50% of patients complete postoperative chemotherapy, and the added benefit to preoperative chemother
Externí odkaz:
https://doaj.org/article/e21bc5ff54f54ceb8cf35f8cf287333a
Autor:
Ettrich, Thomas, Schönsteiner, Stefan, Mayer-Steinacker, Regine, Stilgenbauer, Stephan, Gog, Christiane, Thuss-Patience, Peter, Wolf, Carolin, Ostgathe, Christoph
Publikováno v:
Die Onkologie; November 2024, Vol. 30 Issue: 11 p1046-1052, 7p
Autor:
F. Brandes, J. K. Striefler, A. Dörr, M. Schmiester, S. Märdian, G. Koulaxouzidis, D. Kaul, A. Behzadi, P. Thuss-Patience, J. Ahn, U. Pelzer, L. Bullinger, A. Flörcken
Publikováno v:
BMC Palliative Care, Vol 20, Iss 1, Pp 1-9 (2021)
Abstract Background Soft tissue sarcomas (STS) account for less than 1% of all malignancies. Approximately 50% of the patients develop metastases with limited survival in the course of their disease. For those patients, palliative treatment aiming at
Externí odkaz:
https://doaj.org/article/faa90b044e7343b1a9a54325d4f7c8ab
Autor:
Matthias P Ebert, ProfMD, Nadja M Meindl-Beinker, PhD, Tobias Gutting, MD, Martin Maenz, PhD, Johannes Betge, MD, Nadine Schulte, MD, Tianzuo Zhan, MD, Philip Weidner, MD, Elke Burgermeister, PhD, Ralf Hofheinz, ProfMD, Arndt Vogel, ProfMD, Stefan Angermeier, MD, Claus Bolling, MD, Maike de Wit, ProfMD, Ralf Jakobs, ProfMD, Meinolf Karthaus, ProfMD, Gertraud Stocker, MD, Peter Thuss-Patience, MD, Tobias Leidig, PhD, Timo Gaiser, ProfMD, Jakob N Kather, ProfMD, Nicolai Haertel, MD
Publikováno v:
The Lancet. Healthy Longevity, Vol 3, Iss 6, Pp e417-e427 (2022)
Summary: Background: The overall survival of patients with advanced and refractory oesophageal squamous cell carcinoma, mostly aged 65 years and older, is poor. Treatment with PD-1 antibodies showed improved progression-free survival and overall surv
Externí odkaz:
https://doaj.org/article/44c5e9f98cad4d8cb78f0b4c9de02298